clinical trial · NCT04843319
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
Advanced Prostate AdenocarcinomaVERU-100
brief summary
To determine an effective dose of VERU-100 for the treatment of advanced prostate cancer by assessing its effect on testosterone levels by Day 28 and maintenance through Day 91.
started
Jun 9, 2021
primary completion
Jan 19, 2023
completion
Jan 19, 2023
last updated
May 19, 2023
detailed description
This study is a multicenter, randomized, open-label, dose finding study of VERU-100 to attain and maintain serum total testosterone levels within castrate range (\<50ng/dL) in men with advanced prostate cancer. Stage 1 of the study will assess the effect of VERU-100 at various doses. Stage 2 will further assess the efficacy of the effective doses of VERU-100 in an expanded patient population.
official title
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol